Clinical trials: Lassa Fever, open to volunteers
Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected…
- Trial name
- FIRST-IN-MOP (NCT07833436)
- Testing
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur